Biometric Stock Alert: Nxt-ID Inc. (OTCQB:NXTD) Provides update on the Wocket™ and 3D FaceMatch™ Systems.

SHELTON, CT - October 8, 2013 (Investorideas.com biometrics/ defense stocks newswire) NXT-ID Inc. (OTCQB: NXTD), a biometrics company focused on the growing mobile commerce market, today announced that it has issued the following product update for the Wocket™ and 3D FaceMatch™ Systems.

Mr. Gino M. Pereira, CEO of NXT-ID Inc., notes, "NXT-ID is building an innovative, next generation information security platform using advanced biometric technology to enable secure transactions, identity management, and access control via mobile and other devices in an intuitive, cost-effective and easy-to-use manner. NXT-ID is creating a new paradigm in information security."
He also added, "At the heart of NXT-ID's new paradigm is real-time, dynamic, multi-factor biometric authorization that is user friendly and extremely difficult to hack, thus providing greater security beyond conventional security systems. This system combines multiple attributes that are unique to each user such as face, voice, fingerprint, and retina with multiple attributes that are unique to other identifiable features, such as devices and accounts, to form an impenetrable security solution. By introducing this new paradigm, NXT-ID hopes to shatter the conventional User/Password structure that currently exists."
"The market opportunity for NXT-ID's biometric security products is significant. The Wocket™ alone has a target market of nearly $1B in the U.S. The opportunity will expand across multiple segments, given that the company's products target consumers, enterprise and government agencies in the U.S. and overseas."
NXT-ID's expertise in biometrics, along with its growing patent portfolio of cutting edge technology, gives the company a solid foundation upon which to make the new security paradigm a reality in the marketplace. The product roadmap is ambitious with several new security products scheduled for release in the months ahead, all of which are based off of the company's Mobile-Bio™ platform. NXT-ID is using its Mobile-Bio™ platform to commercialize a range of next generation security products targeted at a range of applications that extends across multiple segments. These products include:
1. The Wocket™ - a new class of biometrically secure mobile devices designed to bring the traditional wallet into the 21st century by providing the functionality of a wallet and incorporating a touch screen and a single dynamically programmable card to use for credit, debit and any other magnetic stripe functions.
2. Mobile-Bio FaceMatch™ - 2D, 3D and pseudo 3D methods to perform facial recognition. Additionally, NXT-ID is seeking to incorporate its patent pending "FacePassword" as a method to add multi-factor face and face movement to Dynamic Pairing Codes using simple low-power embedded processor on an external device (biosensor), such as a Wocket™, that then connects to other end-points using Dynamic Pairing Codes.
3. Mobile-Bio Sensor™ - a simple, web-enabled, biometric-enabled external device that is used for local authentication and remote authentication with the BioCloud™ and/or remote servers.
4. VoiceMatch™ - a unique biometric-enabled method to add multi-factor biometric identifiers (both speech and speaker recognition) to Dynamic Pairing Codes using simple low-power embedded processor on an external device (e.g., BioSensor), such as the Wocket™, that then connects to other end-points using NXT-ID's Dynamic Pairing Codes.
5. Mobile BioCloud™ - a cloud-based end-point (authentication service) to authenticate any "end-point" along a communication path, such as external biosensors such as the Wocket™ and/or other PCs or servers along the path. A dynamic pairing code is sent to the BioCloud™ where it is combined with other "identifiers" (such as device serial number, master key, wallet key, dynamic pairing keys, Firmware key) dynamically (per NXT-ID's proprietary algorithm that selects which identifiers are used when) to issue a response, which is the compared by each end-point.
NXT-ID's Mobile-Bio™ platform is diverse and contains a host of proprietary, next generation security technologies. The diversity of the platform is a key asset. It reflects the experience and depth of the company's management and software developers in biometric technology. The platform enables NXT-ID to produce a range of innovative products incorporating proprietary methods targeted at different applications and market segments that includes m-commerce, enterprise, law enforcement, defense and Homeland Security.
NXT-ID plans to develop and foster market niches targeted at consumers and small business while continuing to serve the law enforcement and defense markets.
The Company is currently testing its 3D FaceMatch system for law enforcement with Palm Bay Police in Florida and is ruggedizing the system for real world conditions. This work is expected to be completed by the end of November 2013 and the 3D facial recognition system is anticipated to be launched for sale to law enforcement and corporations desiring secure access control in December 2013. The Company has hired an in-house sales representative to facilitate demonstrations and sales.
The Wocket development is proceeding well and several key modules have been completed. A manufacturing prototype is anticipated to be completed by December 2013 and sales of this product are expected to commence in the first quarter of 2014. The Company is taking a segmented approach to this very large consumer market and targeting 3 niche markets initially;
a) Students at colleges and universities
b) Organizations that offer members identity protection services, and
c) Banks that wish to offer premier customers a novel, advanced, secure method of payment
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Relations
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: this release was compensated for by NXTD as part of a monthly service for news publication and distribution and content marketing. (five thousand per month plus 144 shares)
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Mining Stock Alert: DNA Precious Metals, Inc. (OCTQB: DNAP) Announces Launch of Corporate Video

Montreal, Canada - October 8, 2013 (Investorideas.com Mining stocks newswire) DNA Precious Metals Inc. ("DNA" or "the Company") (OCTQB: DNAP) is pleased to announce the launch of its corporate video outlining the Company’s focus on gold/silver tailings mining in Montauban, Quebec, Canada. To view the video, please visit www.DNAPreciousMetals.com. The company website offers a user-friendly interface to easily locate information on all topics relevant to the Company. Visitors to the website will learn about industry specific developments and how DNA is positioning itself to address the dynamic gold/silver tailings market.

The website also features the latest corporate news and the ability for visitors to interact with the Company's investor relations team, including the ability to register to receive updates directly from the Company. Management takes this opportunity to remind investors/shareholders that our website will be an important tool for keeping the investment community up to date as the Montauban story develops. DNA will continuously update the website to ensure that its contents remain current and useful to our investors. In addition to news releases, corporate and project information, we invite investors and shareholders to send their emails to ir@DNAPreciousMetals.com to be added to the company's email database for future updates.
"We are very excited about our new corporate video - a true portrayal of the DNA Precious Metals team and their operations in Quebec, Canada. We recognize that not all of our investors/shareholders have the opportunity to visit our mining facilities. This video allows everyone to see first-hand what the company has envisioned for the future, and to meet the strong leadership team that makes DNA an industry innovator," Ronald Mann, CEO.
About DNA Precious Metals, Inc.
DNA Precious Metals, Inc. is focused on near term production of the Montauban tailings mine in the Province of Quebec, Canada with an aggressive search for economic production assets. The company trades on the OTCQB market in the United States under the stock symbol DNAP. For more information, please go to   www.DNAPreciousMetals.com .
On behalf of the Board
Ronald K. Mann, CEO
Forward Looking Disclaimer
This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.
CONTACT INFORMATION
Twitter: www.twitter/dnametals
Facebook: www.facebook.com/dnametals
INVESTOR RELATIONS
Stuart T. Smith, CEO
SmallCapVoice.Com, Inc.
ssmith@smallcapvoice.com
Tel: +1-(512)-267-2430
Skype: SmallCapVoice.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Investorideas is compensated by DNAP for news and content publication and syndication ( October 2013 - five thousand for one month of news distribution on Investor ideas news wire ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Mining Stock Alert: DNA Precious Metals, Inc. (OCTQB: DNAP) Announces New Directors

Montreal, Canada - October 7, 2013 (Investorideas.com Mining stocks newswire) DNA Precious Metals Inc. ("DNA" or "the Company") (OCTQB: DNAP), at the Meeting of the Board of Directors on August 12, 2013 appointed G.E. (Ted) Creber, Q.C,. and Garfield (Gary) J. Last to join Ronald K. Mann on the Board of Directors. With this addition, the DNA Board has two independent directors. All other Directors resigned (as per PR 2013-08-15).

Previously, Mr. Creber was the President/Chief Executive Officer of Consumers Gas Company (n/k/a Enbridge), currently owning and operating Canada’s largest natural gas distribution company located in Toronto, Canada. In 2008 Mr. Creber was a Director of Yukon Gold Corp., a mineral exploration company. Mr. Creber graduated from the University of Toronto with a degree in political science and economics and from Osgoode Hall with a degree in law. He was appointed a Queen’s Counsel in 1965. He has practiced law in the field of corporate and securities law with several major Canadian law firms.
Mr. Last is the President of Mind and Management Corporation, Turks & Caicos, BWI, a company which provides Director and Officer services for Investment Companies resident in the Turks & Caicos Islands, British Virgin Islands and Bermuda. Mr. Last has been a Director and Officer of significant private companies for over 40 years. From 1982 to 1986, Mr. Last was the President and Director of Barrick Gold Corporation, currently the world’s largest gold producer, located in Toronto, Canada. Mr. Last received a Bachelor of Engineering (Chem) Degree from the University of Saskatchewan. He is a Registered Professional Engineer in the Province of Alberta, Canada.
DNA Chairman and CEO Ronald Mann said, "It is a pleasure to welcome Ted and Gary to DNA's Board of Directors. Ted and Gary's experiences with international minerals companies will be a valuable addition to DNA's capabilities to advance our Montauban mining project."
About DNA Precious Metals, Inc.
DNA Precious Metals, Inc. is focused on near term production of the Montauban tailings mine in the Province of Quebec, Canada with an aggressive search for economic production assets. The company trades on the OTCQB market in the United States under the stock symbol DNAP. For more information, please go to   www.DNAPreciousMetals.com .
On behalf of the Board
Ronald K. Mann, CEO
Forward Looking Disclaimer
This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts’ expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company’s future stock price, its revenues or results of operations.
CONTACT INFORMATION
Twitter : www.twitter/dnametals
Facebook : www.facebook.com/dnametals
INVESTOR RELATIONS
Stuart T. Smith, CEO
SmallCapVoice.Com, Inc.
ssmith@smallcapvoice.com
Tel : +1-(512)-267-2430
Skype : SmallCapVoice.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Investorideas is compensated by DNAP for news and content publication and syndication ( October 2013 - five thousand for one month of news distribution on Investor ideas news wire ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Facial Recognition Stocks to Watch: (FB), (HPQ), (NXTD), (SNE), (YHOO)

New York, NY - October 4, 2013 (www.investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biometric and security stocks issues a snapshot for facial recognition stocks.

Biometric technology has become a hot topic in the headlines, from mobile phone security with Apple (AAPL) to analysts predicting biometrics will become mainstream technology in the future. Leading tech companies are introducing fingerprint, facial recognition and voice recognition technology in everything from social media to mobile and gaming.
According to a report on Nextgov.com Hewlett-Packard Company (NYSE :HPQ) has just been awarded a $102.8 million contract to upgrade Homeland Security Department employee identification cards with features that accommodate iris and facial recognition, according to federal funding databases.
Article source
http://www.nextgov.com/emerging-tech/2013/ 10/hp-lands-103- million-dhs-employee-id-contract/ 71174/?oref=ng-HPriver
In late August NXT-ID, Inc (NXTD:OTCQB) a biometrics company focused on the growing m-commerce market announces that its wholly owned subsidiary, 3D-ID, LLC commenced a pilot program with the Palm Bay, FL Police Department to evaluate its 3D FaceMatch™ biometric facial recognition identification systems.
The identification management systems leverage unique and patented FaceMatch™ 3D technology that precisely senses shape at up to a million points on a face without using lasers or projected patterns. This individually unique shape information is compressed into a small 3D biometric template containing a complete 3D shape signature of that individual face. This shape signature is rapidly compared to other templates in a database. Unlike 2D recognition methods where performance is highly variable depending on scene lighting, head pose, facial expression, eyewear, facial hair and cosmetics, FaceMatch™ templates and performance remain invariant over an extremely wide range of imaging variables. This enables reliable, scalable, and convenient face recognition solutions.
The system is being used at Palm Bay to enroll inmates into local detention centers, creating a 3- dimensional database that can be used in the future to potentially identify persons of interest. Inmates that are released will also have their identities verified through 3D facial recognition to prevent the inadvertent release of the wrong individual.
Facebook ( FB) has caused a lot of controversy and buzz in the social media sector as they talk about introducing a facial recognition technology to match faces in photos with public profile features. Facebook acquired a Face.com in 2012 as part of its roll out strategy. ‘ Yahoo ( YHOO ) also recently announced its acquisition of IQ Engines, a start-up company in face and image recognition technologies to use for Flickr.
And now facial recognition and biometrics are coming to a game near you.
According to a recent article Sony (SNE) is incorporating multiple forms of biometrics into the PS4. “With the use of the PS4 Eye Camera, Sony's next-gen console will now have its own champion against the Kinect. According to Joystiq, the PS4 Eye Camera will allow voice and face recognition, so you can easily load up games, navigate the OS, and give in-game commands. This feature will immediately be made available for Knack.”
http://au.ibtimes.com/articles/507521/20130920/ps4-ps3-games-streaming-eye-camera-kinect.htm
So as biometrics enters all phases of every day life, it creates new levels of security and controversy over privacy issues. There is game changing technology to pay attention to for investors.
Research Biometrics Stocks with our stock directory
http://www.investorideas.com/BPS/Stock_List.asp
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights.  Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 or 212-822-8842 Source - www.Investorideas.com

Biometrics Analysts and Experts from Goode Intelligence, Biometrics Institute and NXT-ID, Inc (OTCQB: NXTD) Discuss Recent Hacking of Apple's (AAPL) Touch ID Fingerprint Technology and the Future of Biometrics

Point Roberts, WA, NEW YORK, NY - October 2, 2013 (Investorideas.com biometrics/ defense stocks newswire) Mobile Security Biometrics Alert: Investorideas.com, an investor research portal specializing in investor research in leading sectors, issues a follow up to its recent article , Analysts and Industry Participants Share Insight Into the Future of Mobile Security and Biometrics, following the recent reports of Apple's Touch ID Fingerprint Technology being attacked by professional hackers. Alan Goode, Managing Director of GoodeIntelligence.com, Isabelle Moeller, Chief Executive at Biometrics Institute and Mr. Gino Pereira, Chief Executive Officer of NXT-ID, Inc (OTCQB:NXTD) share insight on the security of Apple's (AAPL) Touch ID and the future trends in biometrics.

Apple bought its technology for $365 million from AuthenTec a year ago and in spite of hacking headlines, most analyst agree the biometric technology is very safe and secure for most users and the wave of biometric technology implementation will continue.
Alan Goode, Managing Director of GoodeIntelligence.com, who has been predicting the implementation of biometrics in smartphones for some time said "There is no doubting that Apple's Touch ID can be fooled into accepting fake (lifted) prints but it does take a relatively high level of forensic and material sciences skills which will be outside the skills of most people. There is always a trade-off between security and convenience and I feel that for the one-touch capability of unlocking a mobile device, Touch ID does a very good job. Apple may need to review security measures if it wants to extend the functionality of Touch ID to enterprise and commercial applications. I always maintain that two or multi-factor authentication is required to validate identity for high risk tasks such as making a financial payment. Apple may want to include a second or third factor for this type of function."
Mr. Gino Pereira, Chief Executive Officer of NXT-ID, Inc. http://www.nxt-id.com/, who has over 30 years of executive, operational and financial experience with technology companies in the United States, Europe and the Far East agrees with Mr. Goode saying, " there are varying degrees of security that are effective depending on the application. Password hacking can be done anonymously from a long distance, whereas hacking fingerprints requires a more complex personal attack. It requires more effort, equipment and personal access to the actual person; and because it's so much more complex the payoff has to be worth the effort. Apple should be applauded for bringing innovative biometric technology to the consumer. "
He also went on to say that using multimodal identification at the same time, such as password and fingerprint recognition creates a higher level of security.
His company is launching its innovative MobileBio™ suite of biometric solutions, starting with the Wocket™ an advanced secure electronic wallet that will use voice biometrics, later this year.
His company's subsidiary, 3D-ID LLC deploys 3D facial biometric identification and has 22 licensed patents.
Isabelle Moeller, Chief Executive at Biometrics Institute released the following news earlier today addressing the iPhone fingerprint technology attack. They noted the group claiming success, known as the Chaos Computer Club from Germany has been involved in similar biometric attacks.
"The BVAEG - a subcommittee of the independent Biometrics Institute - consists of many of the most experienced experts in this area from around the world," says Isabelle Moeller, Chief Executive of the Biometrics Institute, "the BVAEG mission is to raise awareness of the need for vulnerability detection to be included with biometric devices, to promote standards, enhance privacy protection, performance measures and testing, and to help facilitate the dissemination of new research or findings in this area."
Their press release also quoted Tsutomu Matsumoto from Yokohama National University, a member of BVAEG, as saying "the current attack requires the lifting and processing of a high quality latent fingerprint at high resolution in order to make a successful spoof. These factors should be considered when assessing this attack's impact under realistic usage scenarios."
The Biometrics Institute encourages manufacturers of equipment that include biometrics sensors to be proactive in adopting spoof detection technology to maximise the chance of successfully rejecting a biometric spoof, and also recommends government agencies and top-level decision makers be aware of the need for appropriate biometric vulnerability testing and certification as they consider both the risk and the convenience of the security mechanism(s).
In terms of the future most analyst see biometrics going mainstream and that Apple's Touch ID has paved the way. Gino Pereira sees a future down the road where we will be wearing a device that will monitor us biometrically to provide access to everything we need.
Original Sept 16 th article:
Analysts and Industry Participants Share Insight Into the Future of Mobile Security and Biometrics
http://www.marketwired.com/press-release/analysts-industry-participants-share-insight-into-future-mobile-security-biometrics-1830861.htm
About www.InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Contact Information
Investorideas.com
800-665-0411
or 212-822-8842

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Renewal of DARPA Dialysis-Like Therapeutics Contract

SAN DIEGO - September 26, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Defense Advanced Research Projects Agency (DARPA) has exercised an option agreement to proceed with year-three of a five-year $6.8 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program.

The third year of Aethlon's DLT contract contains eight milestones representing a potential of $1,534,099 in revenue opportunity. To date, Aethlon has invoiced $3,188,131 to DARPA for achieving fourteen of sixteen milestone objectives targeted in the first two years of the DLT program.
The goal of the DLT program is to develop a portable device that removes "dirty" blood from the body, separates harmful agents, and returns "clean" blood to the body in a manner similar to dialysis treatment of kidney failure. The resulting device would decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States annually. In the DLT program, Aethlon has been contracted to utilize the Aethlon ADAPT™ system to create an extracorporeal blood purification cartridge that selectively eliminates sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The Aethlon ADAPT™ converges advanced plasma membrane technology with high affinity drug agents to allow the selective yet rapid clearance of disease targets from the entire circulatory system without damaging blood cells or removing particles essential for health. Aethlon has also been contracted to develop a novel blood circulatory instrument that will deliver ADAPT™ based and other therapeutic filtration devices without systemic anticoagulants normally required in extracorporeal therapies.
Beyond the civilian need for anti-sepsis therapies, the device proposed in the DLT program would play an important role in saving the lives of wounded U.S. military personnel, as infection leading to sepsis is a significant cause of mortality. When sepsis is complicated by shock, approximately half of patients do not survive for 30 days, even if effective antibiotics are used. Unfortunately, the fatality rate from sepsis can be high, given that antibiotic-resistant bacteria are an increasing problem for injured warfighters and military treatment facilities. Bio-agents engineered for resistance against antibiotics also represent a significant threat to both warfighters and citizens. Current culture-based methods of identifying blood-borne pathogens can take 48 hours or longer to identify the offending pathogen, and some blood-borne pathogens do not propagate in culture. Pending these culture results, septic patients are treated with protocol-based broad-spectrum antibiotics. In the event the offending pathogen is resistant to the empirically chosen antibiotic, the fatality rate may increase as much as 9% per hour.
Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). Under the IDE, Aethlon will enroll ten end stage renal disease (ESRD) patients infected with HCV as part of a feasibility study to demonstrate Hemopurifier safety. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and other disease conditions.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Technology Today Radio: Apple (AAPL) giving us another reason to Give the Finger: Ajay Gupta interviews Biometrics Expert Gino Pereira, CEO of NXT-ID (NXTD)

New York, NY - September 26, 2013 (www.investorideas.com newswire) Investorideas.com, an investor research portal specializing in independent research in leading sectors including biometrics and mobile security stocks features a recent in interview with NXT-ID, Inc.(OTCQB: NXTD). Technology Today blog radio host Ajay Gupta interviews biometric expert Mr. Gino Pereira, CEO of NXT-ID (OTCQB: NXTD) to discuss recent developments in biometrics and how Apple (AAPL) is taking the lead in mobile security. Gino shares insight into what works now, what doesn’t work and the future of biometrics as it becomes mainstream technology.

Technology Today ;Apple giving us another reason to Give the Finger
Ajay Gupta interviews Gino Pereira, CEO of NXT-ID (OTCQB: NXTD )
Intro -
Apple's new OS, iOS 7, and two new phones, the iPhone 5c and 5s, have received a lot of attention. And they've sold 9 million phones in the first weekend of sales.
One feature that hasn't received as much discussion as may be deserved is the fingerprint biometric feature.  That's the kind of tech we like to discuss at Technology Today and we'll do that this Wednesday at 6pm EST.
Security is an ever growing concern and the 4-digit pass code is often more of an annoyance than a deterrent. Perhaps a finger tap approach, which we are used to anyway from opening apps, will do better? 
Some say this is a slippery slope that once we are accustomed to using our fingers, retina scanners, voice print and other more intrusive biometric approaches will become the norm.
The show discuses the pros and cons and takes a deeper look at the biometric teck. Gino Pereira, CEO of NXT-ID, is a recognized expert in the technology space having built start-ups across the world.  His current business, NXT-ID, is active in biometrics with special application in mobile payment security.
Hear the September 25th radio show http://www.blogtalkradio.com/technologytoday/2013/09/25/apple-giving-us-another-reason-to-give-the-finger

Mr. Gino Pereira

MobileBio™ facematch™

About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID’ wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights.  Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 or 212-822-8842 Source - www.Investorideas.com

Powerdyne International, Inc. (OTCBB: PWDY) Appoints Manufacturing Veteran of 35 Years as Its New Operations Manager

WARWICK, RI - September 25, 2013 (Investorideas.com renewable energy stocks newswire) Powerdyne International, Inc. (PWDY), a manufacturing company that builds and leases electrical generation equipment, today announced the appointment of James O'Rourke as its new Operations Manager. O'Rourke brings more than thirty-five years of manufacturing experience from conception to production to the rapidly growing development stage electrical generator manufacturer. He will take over the helm of Operations Manager effective immediately.

Company President Dale Euga said, "O'Rourke's extensive experience in managing the manufacturing and operational side of development stage companies, as well as his understanding of acquisitions and mergers, will be an essential component to Powerdyne's success."
Euga also said that Mr. O'Rourke will be instrumental in planning the design of the manufacturing facility, the set up assembly line, the marshaling of the component systems, and oversight of the integration of computer sensor programs in all aspects of Powerdyne International's design and operational systems.
About Powerdyne International, Inc.:
Powerdyne International, Inc. (www.Powerdyneinternational.com) is a manufacturing company that builds and leases electrical generation equipment including its own portable electrical power generation equipment called PDIGenset (which is patent and trademark pending).
The PDIGenset is a self-contained generator using a modified radial air cooled aircraft engine to drive a 1-megawatt (MW) generator. The PDIGenset, runs on natural gas, propane or almost any gaseous fuel. It is compact, lightweight, clean burning, produces low emissions and is extremely energy-efficient.
PDIGensets are designed to be installed at virtually any location. The genset is leased and maintained by PDI. Although the company's target customer will typically use its PDIGenset to produce its own primary electrical power, it can be used for emergency back-up power generation and is useful in any situation where reliable power is needed.
PDI is founded on the ability to produce primary electrical power using proprietary technology to power electrical generation equipment which makes electricity cheaper than existing means of producing primary electric power. PDI expects that the difference between its cost of generating electricity over its customer's current cost will result in substantial savings to the customer.
For more information on Powerdyne International go to: www.Powerdyneinternational.com
This release may contain "forward-looking statements" that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's current expectations about its future plans and performance, including statements concerning the impact of marketing strategies, new product introductions and innovation, deliveries of product, sales, earnings and margins. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company's most recent Form 10-K and subsequent filings with the Securities and Exchange Commission for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.
Contact:
Powerdyne International, Inc.
contact@powerdyneinternational.com

Biometric Stock Alert: NXT-ID, Inc. (OTCQB:NXTD) Appoints New Director with CTO, CIO and COO Experience at Major E-Commerce and Social Consumer Brands

Shelton, CT - September 25, 2013 (Investorideas.com biometrics/ defense stocks newswire) NXT-ID, Inc. (OTCQB:NXTD) a biometrics company focused on the growing mobile commerce market, today announced the appointment of Dr. Michael J. d'Almada-Remedios to its Board of Directors. Dr. Remedios joins the company as an independent director, advising in key areas of technology development.

Dr. Remedios lends more than twenty years of experience in executive, product, technology and operations leadership as CTO, CIO, and COO. He has held key management positions at major e-commerce and social consumer brands including eBay/Shopping.com, Expedia/Hotels.com, Travelocity/Lastminute.com, Kmart/BlueLight.com and Wells Fargo Bank.
Mr. Gino M. Pereira, CEO of NXT-ID, Inc. said, "We are delighted to welcome Mike to the Board of NXT-ID. His extensive e-commerce and banking experience will be invaluable to the Company as we launch our mobile security products, including the Wocket™. His experience is a terrific complement to the government markets background that our current independent board member Major General David Gust (Ret.) provides. The majority of our Board now comprises independent Board Members."
Dr. Remedios commented on his joining the Board, "I'm delighted to join the NXT-ID Board at this exciting time of online, offline, mobile and social convergence. There are many emerging 'Omni-channel' developments coming out of established and start-up companies. The technology of NXT-ID is perfectly positioned to be a 'low friction' accelerator for partners and its own unique products such as the Wocket."
Dr. Remedios' background includes a successful track record for product innovation and development, outsourcing, global platform integration, massive-scale/hyper-growth operations, and building/developing teams from 50 to more than 500 people. His key accomplishments across the board at each company consistently show impressive gains in sales, profitability and global expansion into new markets.
At eBay, he was a member of the eBay Inc. Technology Board for eBay, PayPal and Skype. He was also a key member of the eBay Inc. workgroups for defining and driving the next-generation consumer experience "Finding 2.0," "on-eBay" and the Advertising and Distributed Commerce Network offering "off-eBay."
At Expedia, Inc., he reported to the President of Hotels.com and Venere.com and was responsible for all technologies, product development and technical operations for Hotels.com and Venere brands, including "One H," the global integration of business and technology for Hotels.com and Expedia, Inc.
At the Travelocity group of companies, he reported to the CEO of Lastminute.com. As Global CIO of the Lastminute.com group and Travelocity Europe, he managed 350 staff delivering all aspects of technology worldwide.
Additionally, his earlier career included six years as Vice President and Manager, Systems Integration & Development at Wells Fargo Bank, Consumer Banking Group.
Mr. Remedios recently joined software company, Swarm-Mobile (http://www.swarm-mobile.com) as the COO and CTO.
NXT-ID, Inc. is a technology company that is developing and marketing products, solutions, and services for consumers and organizations that have a need for biometric secure access control. The Company has three distinct lines of business: mobile commerce, law enforcement, and biometric access control applications.
The first product to be launched in the MobileBio™suite for consumer markets will be the Wocket™. Currently in development, this next generation digital wallet aims to reduce the number of cards in a wallet, while supporting virtually every payment method currently available at Point-of-Sale (POS).
The Company also recently announced that its wholly owned subsidiary, 3D-ID, LLC commenced a pilot program with the Palm Bay, FL Police Department to evaluate its 3D FaceMatch™ biometric facial recognition identification systems.
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Relations
Jared Mitchell
Managing Director
ProActive Capital
www.ProActiveCapital.com
Direct: 646.863.6274
Cell: 917.453.0637
jmitchell@proactivecapital.com
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: this release was compensated for by NXTD as part of a monthly service for news publication and distribution and content marketing. (five thousand per month plus 144 shares)
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.

SAN DIEGO - September 24, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), announced today that Dr. Cicek Gercel-Taylor has been appointed Clinical Research Director of Exosome Sciences, Inc. (ESI), a wholly-owned diagnostic subsidiary of Aethlon Medical. In this role, Dr. Gercel-Taylor will direct and plan the execution of diagnostic clinical programs and interact with collaborative partners and regulatory authorities.

Aethlon Medical develops therapeutic devices to address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Company is preparing to launch the first U.S. studies of the Aethlon Hemopurifier� as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier� is a first-in-class device that targets the rapid elimination of viruses and cancer glycopathogens, including disease-promoting exosomes from circulation.
Exosome Sciences was recently launched by Aethlon to be a stand-alone organization that pursues exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. ESI's lead product, an Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
Dr. Gercel-Taylor stated, "I am very excited to join Exosome Sciences as the Clinical Research Director. This is a very timely opportunity to develop clinically relevant exosome-based assays to enhance patient care with regard to risk assessment, diagnosis and treatment. The conditions are not limited to but include cancer, cardiovascular, and neurodegenerative diseases, in addition to pregnancy complications and viral infections. Exosomes have ideal properties as biomarkers with their stability, ease of isolation and reflecting disease states. The ELLSA will enable the efficient development of disease specific and efficient platforms that can be standardized for clinical utilization. I have been involved in the development and characterization of exosomes since the early days three decades ago. I believe that we are ideally positioned to achieve this goal with our team at Exosome Sciences in collaboration with Aethlon Medical."
About Dr. Gercel-Taylor
Dr. Cicek Gercel-Taylor has been a pioneer in the field of exosome biology and in defining their nucleic acid and protein cargoes. She previously worked at the Department of Obstetrics, Gynecology and Women's Health at the University of Louisville School of Medicine since 1992, and also is the Resident Research Coordinator. Her main research interest is in gynecological cancers, where she investigates the consequences of exosomes on genetic and epigenetic alterations induced in normal host target cells. She has explored the role of endogenous and exogenous hormones in modulating exosomal cargoes and the resulting effects on pathologic processes. A significant part of these investigations includes the identification and characterization of clinically relevant biomarkers, specifically proteomic and miRNA content of pathology-derived exosomes. Dr. Gercel-Taylor is the wife of Dr. Douglas Taylor, who was recently appointed Chief Scientific Officer of Exosome Sciences.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT� System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT� product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Medical Technology Q&A with Chairman and CEO of Aethlon Medical (OTCQB: AEMD) Discussing Launch of New Subsidiary, Exosome Sciences, Inc.

Point Roberts, WA, New York, NY - September 24, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues an exclusive Q&A with Jim Joyce, Chairman and CEO of Aethlon Medical, Inc. (OTCQB:AEMD). Mr. Joyce discusses the recent launch of its new Exosome Sciences, Inc. (ESI) and what that potentially represents to Aethlon and its shareholders.

Q: Investorideas.com
Jim on September 12 th you announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary previously established by Aethlon. Can you tell investors the focus behind the subsidiary and why the timing was right to launch now?
A: Jim Joyce, Chairman and CEO
The rationale for launching Exosome Sciences was driven by the belief we could transform an unvalued asset into a substantially valued asset that would benefit our shareholders. As the focus of Aethlon Medical is therapeutic devices, the market had little reason to assign any value to candidate diagnostic products as our resources are going to be dedicated toward clinical progression and future commercialization of the Aethlon Hemopurifier® and other pipeline therapies. Especially, now that FDA has approved an IDE that allows us to initiate the first human clinical studies of our Hemopurifier® in the United States.
Still, it became increasingly clear that we needed to leverage our proprietary techniques to isolate and quantify exosomes before the window for related diagnostic innovation began to close. It was also hard to ignore the lofty valuations being awarded to other similar-stage molecular diagnostic organizations. So, we launched Exosome Sciences as a stand-alone entity and hired the best-known researchers in the exosome field to unlock the value of our technology and build an expansive pipeline of urine and blood based diagnostic products.
Q: Investorideas.com
Can you explain to investors what Exosomes are and how they play a role in cancer diagnostics and treatment?
A: Jim Joyce, Chairman and CEO
Sure, but I would first like to share that when we first initiated our exosome research programs, the vast majority of the medical community considered these particles to be nothing more than cellular debris with no biological function. In fact, at the time only a handful of labs were thinking about the role of exosomes. Today, it appears our early entry into the field may pay off as the medical community clearly recognizes that exosomes are vital therapeutic and diagnostic targets. In fact, there are now industry conferences and associations dedicated solely to exosome research.
As it relates to the exosome-related objectives of Aethlon Medical, we utilize our Hemopurifier® to target the elimination of circulating tumor-secreted exosomes as an adjunct therapy to improve cancer treatment outcomes. Our strategy addresses a significant unmet medical need as researchers have discovered that exosomes suppress the immune system of cancer patients and they facilitate tumor growth, seed the spread of metastasis, and contribute to drug resistance. Our hope is that exosome elimination saves lives by tipping the therapeutic balance in favor of the patient.
In regards to the diagnostic focus of our Exosome Sciences subsidiary, we are advancing exosome-based tools to better diagnose and monitor the progression of cancer and other life-threatening disease conditions. As it turns out, exosomes transport markers specific to the origin disease into bodily fluids, including the blood and urine where they can be easily assessed. Our objective is to introduce non-invasive liquid biopsies that can provide for the earliest detection or recurrence of cancer and other diseases. Our lead product is an assay that we named ELLSA. So far, ELLSA has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, and breast cancer.
Q: Investorideas.com
Exosome Diagnostics recently announced it entered into a collaboration agreement with Eli Lilly and Company (LLY) for biomarker discovery and validation using Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit. Eli Lilly will gain early access to Exosome Diagnostics technology to help identify key gene mutations and expression levels in blood that may be correlated with drug response and disease recurrence.
Your core technology, the Aethlon Hemopurifer®, targets the rapid elimination of infectious disease and cancer glycopathogens, including exosomes from circulation. Can you tell us the synergies and benefits of having both a therapeutic technology and a diagnostic division working on such an important area of cancer research? And does having a diagnostic and therapeutic division so tightly focused give your company an edge?
A: Jim Joyce, Chairman and CEO
Excellent question. There is tremendous synergy as the advancements of Exosome Sciences have the potential to become companion diagnostic tools that determine when Hemopurifier® therapy should be administered. As an example, an assay able to detect exosomes underlying breast cancer might define the point when it would be appropriate to initiate Hemopurifier® therapy. This same assay would then be useful in monitoring patient response to therapy and could be utilized to optimize the administration of the Hemopurifier® and other therapeutic regimens.
Q: Investorideas.com
You just reported the appointment of Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc. What does his background bring to the table to help lead this new subsidiary?
A: Jim Joyce, Chairman and CEO
Dr. Taylor is the individual who first discovered tumor-secreted exosomes and is a leading published author in the field. His knowledge, expertise, and stature within the scientific community will be instrumental in developing a product pipeline and establishing strategic industry relationships.
Q: Investorideas.com
In closing, your company has achieved some significant milestones recently for Aethlon Hemopurifer®. For investors new to the company, can you give us the recent highlights?
A: Jim Joyce, Chairman and CEO
Since the beginning of the year, we have been extremely productive. Beyond the formal launch of Exosome Sciences, we formed a team that won a $22 million Department of Defense contract, we reported on positive Hepatitis C (HCV) treatment outcomes from studies conducted overseas, we expanded the potential indications of our Hemopurifier® in cancer, and disclosed the issuance of new patents that further protect our technologies.
However, the most significant milestone by far was FDA approval of an IDE that allows us to initiate clinical studies of HCV patients in the United States. While this took years of effort, the IDE approval unlocks the opportunity to demonstrate the value of our Hemopurifier® on the world’s most important clinical stage.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights.  Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 or 212-822-8842 Source - www.Investorideas.com

Biometrics Stocks Take Center Stage As Apple (AAPL) iPhone Sales Soar

New York, NY - September 23, 2013 (www.investorideas.com newswire) Investorideas.com, an investor portal specializing in sector research including biometrics and mobile security stocks, issues an updated directory for biometrics stocks following Apple’s report of selling over 9 Million iPhones over the weekend that incorporate biometric technology.

The new biometric Touch ID fingerprint technology has resulted in a new wave of interest in biometric technology and related stocks within the sector. Shares of Precise Biometrics, Fingerprint Cards, ImageWare Systems and NXT-ID, Inc have all benefited from the new buzz created by Apple’s implementation.
Additionally the biometric sector has made headlines as the Department of Homeland Security tests facial recognition technology and leading companies including Facebook (NASDAQ: FB) add facial recognition to their platforms .
Apple Reviews
Walter S. Mossberg of The Wall Street Journal recommends iPhone 5s "for anyone looking for a premium, advanced smartphone." He calls the phone’s Touch ID fingerprint sensor "a potentially game-changing hardware feature" and iOS 7 "a radically new operating system."
Ed Baig of USA Today looks at both iPhone 5s and iPhone 5c. On the iPhone 5s, he writes, "Taken in totality, the features new to the iPhone 5s make what I consider to be the best smartphone on the market even better." He concludes, "I can strongly recommend either new iPhone but especially the 5s."
David Pogue of The New York Times posts two stories. In his iOS review he writes, "The structure, layout and features represent some of Apple’s best work." In his iPhone review, he calls iPhone 5c "a terrific phone," noting, "The price is right. It will sell like hot cakes." On iPhone 5s, he’s impressed with the improved camera and says the best part of Touch ID is "it actually works — every single time, in my tests. It’s nothing like the balky, infuriating fingerprint-reader efforts of earlier cellphones."
Source - Apple
Directory Preview
Accenture plc ( NYSE:ACN ) is a global management consulting, technology services and outsourcing company, with approximately 266,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments.  Biometrics : Accenture has managed numerous initiatives to improve US-VISIT biometrics through IDENT, including data integration across the Department of Homeland Security and significant biometric data quality enhancements.
Aware Inc ( NasdaqGM: AWRE ) is a leading software and technology supplier for the biometrics, telecommunications, and healthcare industries. Aware's biometrics software products and services are provided to solution vendors and system integrators for use by government agencies towards applications including border management, secure credentials, law enforcement, and national defense. Aware's DSL Service Assurance Group offers test and diagnostics software products that enable broadband service providers to manage their DSL networks. Aware also provides standards-based medical imaging software products to the healthcare industry.
Fingerprint Cards AB ( Stockholm:FING-B; Frankfurt:FPQ ; OTC:FGRPF ) markets, develops and produces biometric components and technologies that through the analysis and matching of an individual’s unique fingerprint verify the person’s identity. The technology consists of biometric sensors, processors, algorithms and modules that can be used separately or in combination with each other. The competitive advantages offered by the FPC’s technology include unique image quality, extreme robustness, low power consumption and complete biometric systems. With these advantages and the ability to achieve extremely low manufacturing costs, the technology can be implemented in volume products such as smart cards and mobile phones, where extremely rigorous demands are placed on such characteristics. The company’s technology can also be used in IT and Internet security, access control, etc.
ImageWare Systems, Inc. ( OTC:IWSY ) is an identity management innovator that has provided advanced biometric solutions to traditional identity markets for more than a decade. Today, we are also using our proven, patented, multi-modal biometric advances to deliver revolutionary mobile capabilities to the wireless, financial services and healthcare sectors. Our cutting-edge IWS CloudID and IWS Interactive Messaging System platforms are enabling extraordinary modular, flexible and scalable identity solutions across a variety of markets. And the PillPhone® is a unique mobile health management application designed to help patients better adhere with recommended medical treatment.
NXT-ID, Inc. ( OTC:NXTD ) Mobile Security for a Mobile World - innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms. NXT-ID’ wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/ , http://3d-id.net/
Precise Biometrics AB ( OTC:PRBCF ; OMX:PREC ) is a market-leading provider of solutions for fingerprint recognition to prove people's identities. With top-of-the-line expertise in fingerprint verification, Precise Biometrics offers fast, accurate and secure authentication of a person. The technology adds value to ID, enterprise and bank cards as well as access to mobile solutions (smart phones and tablets), computers and networks. Precise Biometrics serves business and government organizations throughout the world and its technology is licensed to close to 160 million users.
Research more Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights.  Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - or 212-822-8842 Source - www.Investorideas.com

Entertainment Alert: Interview with Award Winning Producer, Rhode Island Businessman and Investor Chad A. Verdi; Betting on the Best and Taking Risks

New York, NY, Point Roberts, WA - September 19, 2013 (www.investorideas.com newswire Entertainment and Financial alert) Investorideas.com, an investor research portal specializing in sector research for independent investors features an interview with and insight into entrepreneurial producer, businessman and investor Chad A. Verdi of Rhode Island. A self-made businessman, Chad always takes big risks and passionately vests himself in each endeavor he takes on.  From his role as an award winning producer and film-maker over the past decade, to now taking on a role as the largest investor in biometric mobile security company NXT-ID, Inc., (OTCQB: NXTD) Chad lives by the motto "go big or go home".

Q&A Interview
Q: Investorideas.com
Chad you are the American dream in action with your multiple roles in business. Can you give us some background and history of your entrepreneurial journey?
A:Chad A. Verdi
At 18 years old I acquired my first business, a Rhode Island television listing newspaper called TV Facts, which is still in publication today.
In the years leading up to the age of 21 I acquired several other businesses in the food service sector throughout RI. By age 30, I owned, co-owned, served as principal or had investments in over a dozen businesses that ranged from the food industry and toy manufacturing to restaurants and hi-tech developments in the biotechnology field and nuclear waste management.
Over the last 15 years, I have been involved in over $1 billion of business mergers, reverse mergers, start-ups and acquisitions. I currently own, co-own or have investments in more than two dozen businesses in diversified industries with more than 1000 local employees and sales of more than $100 million nationwide.
I also hold a large real estate portfolio that includes the 175-year-old former United Methodist Church in East Greenwich where the constitution of RI was adopted.
Through my production companies, Verdi Productions and Woodhaven Production Company , I have produced six featured films over the last 38 months
In July 2013, I became the largest independent shareholder in the biometric mobile security company NXT-ID, Inc. (OTCQB: NXTD) (http://nxt-id.com/). This is my newest venture outside the film industry.
Q- Investorideas.com
I think the first question for anyone looking at the diverse background in business is what motivates you and what do you look for in a business venture?
A: Chad A. Verdi
What motivates me is being able too look outside the box, seeing things others can't or are overlooking. When you can achieve that, the sky's the limit on what your maximum potential in an investment can be. In the case of NXT-ID, Inc , they have the products in a space that I feel has huge potential. Mobile security is what everyone is talking about now; it's a very hot sector. Their 3D facial recognition is leading technology. Their first product, the Wocket, which is launching this fall, sets the stage for the roll-out of their Mobile suite of products. Just like my other investments in Apple and Yahoo, they were leaders in their respective markets and being first pays off big time!
Q- Investorideas.com
In respect to your role as film-maker and producer, can you give us some background on your companies Verdi Productions (VP) and The Woodhaven Production Company?
A: Chad A. Verdi
My production company, VP was founded in 2009 as an independent and fully-funded media production company based in New York City and RI. We just completed our sixth feature film within the last 38 months, 'A Bets a Bet'. VP will produce the bigger budget films while The Woodhaven Production Company focuses on films under 2.5 million dollars. Both companies are positioning themselves to be serious contenders in the film industry.
Q- Investorideas.com
For a new company in the entertainment industry, you have attracted some very impressive names and talent to your team. I just read that you signed Oscar winners Martin Scorsese and Bruce Cohen along with Ben Younger and Emma Tillinger Koskoff to your next project (Bleed for This). How excited are you about working with them and how did all of this come about?
A: Chad A. Verdi
I am extremely excited about the caliber of talent attached to this project. This film is the reason my wife Michelle, (head of music and talent) and I got involved in this business. Having Ben, Martin, Bruce, and Emma involved elevates this project to a whole new level. It all started with the great script Ben wrote, the writer/director and the leader of our team. He is a true gem.
Q- Investorideas.com
Your recent investment in NXTD-Inc. is in a sector that is making all the headlines now as Apple talks about biometrics technology for its smartphones. When did you first get involved as an investor and what inspired you to take the risk? What are some examples of other stocks in your current portfolio?
A: Chad A. Verdi
I started investing in NXT-ID, Inc over a year ago, knowing it was a huge risk if the company could not deliver on what they stated they could. My best scenario was correct and they delivered on their first revenue stream in biometrics, then delivered on becoming public and soon they will deliver their first of its kind 'digital wallet' prototype of the Wocket. They have taken a different approach with Wocket; reducing the number of cards in your wallet while supporting virtually every payment method currently available at retailers around the world. I bought both Apple ( AAPL) and Yahoo (YHOO) at very low prices. I feel NXT-ID has the same upside potential as those two did in their early stages.
Q- Investorideas.com
In closing what is on the horizon for you as both a film-maker and an investor?
A: Chad A. Verdi
The Bleed for This project, is very important to me and my family. Bleed For This tells the true-life story of world champion Rhode Island boxer Vinny Pazienza as he recovers from a near fatal car accident and goes on to win three additional world boxing titles, one of the most incredible and dramatic comebacks in sports history. We want Vinny's story told to share his great achievement with the world.
As an investor, NXT-ID, Inc (OTCQB: NXTD) could change the world we live in as we all go mobile. That's pretty cool!
About the Verdi Productions and Woodhaven Production Company:
Both Verdi Productions and The Woodhaven Production Company are fully funded film production companies, covering all aspects of filmmaking - from conception of script through postproduction.
http://www.woodhavenfilms.com/, http://www.verdifilms.com/
About InvestorIdeas.com:
www.InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech stocks tech and mobile stocks, mining, energy, waters stocks, renewable energy stocks, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares Disclosure: Chad a Verdi is long NXTD
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source www.Investorideas.com